and hospitalization for heart failure in the overall study population, Combined endpoint of all-cause mortality, kidney failure
Conditions
Brief summary
Time to the composite endpoint of all-cause mortality, kidney failure (chronic dialysis, kidney transplantation or death due to kidney failure), and hospitalization for heart failure
Detailed description
Time to kidney failure (in advanced CKD and transplant patients only), Time to the first occurrence of heart failure hospitalization, Time to all-cause death, In addition, it will be investigated whether dapagliflozin is superior to placebo in reducing the incidence of the composite outcome of all-cause mortality, kidney failure, or heart failure hospitalization in each of the three subpopulations.
Interventions
DRUGDAPAGLIFLOZIN
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to the composite endpoint of all-cause mortality, kidney failure (chronic dialysis, kidney transplantation or death due to kidney failure), and hospitalization for heart failure | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to kidney failure (in advanced CKD and transplant patients only), Time to the first occurrence of heart failure hospitalization, Time to all-cause death, In addition, it will be investigated whether dapagliflozin is superior to placebo in reducing the incidence of the composite outcome of all-cause mortality, kidney failure, or heart failure hospitalization in each of the three subpopulations. | — |
Countries
Belgium, Germany, Netherlands, Spain
Outcome results
None listed